Abstracts

532 – HIV Remission After Allogeneic Hematopoietic Stem Cell Transplant From CCR5Δ32/Δ32 Sibling Donor

Background To date, a few cases of HIV remission after allogeneic hematopoietic stem cell transplantation (HSCT) have been reported. While most involved CCR5Δ32/Δ32 donors, there have been recent reports of remission without this mutation, suggesting that factors beyond CCR5 might be sufficient for remission. Further reports of HIV remission are crucial to understand the factors that influence the…

513 – HIV-1 Reservoir Decay During Broadly Neutralizing Antibody Therapy in the RIO Trial

Background Antiretroviral therapy fails to eliminate a reservoir of HIV-1 infected cells wherein the provirus is transcribed at levels insufficient to induce cell death. Earlier studies of broadly neutralizing antibodies (bNAbs) administered during ART interruption (ATI) showed mixed results with some reporting accelerated reservoir decay. RIO enabled examination of reservoir dynamics in 32 individuals receiving…

787 – Immune Tumor Microenvironment of HIV-Associated Lung Cancer Reveals Immunoregulatory Features

Background Lung cancer is the leading cause of cancer mortality among people with HIV (PWH), with increased incidence and poor outcomes.  Methods We explored whether HIV-associated non-small cell lung cancers (NSCLC) harbor  an immunoregulatory tumor microenvironment (TME) that limits tumor-specific responses. A tissue microarray was constructed with tumors from 18 PWH and 19 people without…

658 – Integrase Inhibitor- Versus Protease Inhibitor-Based Therapy for People With Advanced HIV Disease

Background To date clinical trials have been underpowered to assess the preferred antiretrovirals in therapy-naïve people with advanced HIV disease (PWAH). We investigated the efficacy and safety of an integrase inhibitor (INI) versus a boosted protease inhibitor (PI) containing regimen in PWAH. Methods In this open-label, randomised, multicentre, non-inferiority trial, therapy-naive people with HIV aged…

690 – Long-Acting Injectable ART in Persons With HIV-1 Viremia in the South: A Tool to End the Epidemic

Background Treatment with long-acting antiretroviral therapy (LA ART) with cabotegravir/rilpivirine (CAB/RPV) +/- lenacapavir (LEN) holds promise to achieve viral suppression (VS) in people with HIV (PWH) for whom oral ART fails. Although supported in certain scenarios by guidelines, scaling this approach in viremic PWH has lagged Methods We performed a retrospective review of PWH cared for…

719 – Metformin on Time to Sustained Recovery in Adults With COVID-19: ACTIV-6 Randomized Clinical Trial

Background The effect of metformin on reducing symptom duration among low-risk, outpatient adults with mild to moderate coronavirus disease 2019 (COVID-19) has not been studied. Our objective was to test metformin compared to placebo for symptom resolution during acute infection with SARS-CoV-2.  Methods The ACTIV-6 platform clinical trial evaluated repurposed medications for mild to moderate…

720 – Optimal Timing and Immunogenicity of COVID-19 Booster Vaccination: The EU-COVAT-2 BOOSTAVAC Trial

Background Currently, optimal timing and/or number of booster COVID19 vaccinations remains unclear. We compared immunogenicity and safety of mRNA booster vaccination at different time intervals. Methods In a randomised, controlled, multicentre, phase II trial, adults with >3 prior mRNA COVID19 vaccines, with last vaccine 3 to 7 months (M) prior, were randomized to one of…

553 – Targeting of HIV-Infected Clones by Cognate Peptide Stimulation and Antiproliferative Drugs

Background Clonal expansion of HIV infected CD4+ T cells is a barrier to HIV eradication. Previous studies suggested that blocking cell proliferation can accelerate reservoir decay. We recently described a marked reduction in clonally expanded infected CD4+ T cells in a patient with elite control (ES24) after chemoradiation for lung cancer with paclitaxel and carboplatin.…

653 – TFV-DP Is Associated With Baseline Virologic Suppression in PWH on TAF: Results From ACTG A5359

Background Tenofovir (TFV)-diphosphate (TFV-DP) concentrations in dried blood spots (DBS) demonstrate strong associations with adherence, virologic suppression (VS) and future viremia in persons with HIV (PWH) but data are limited to the older TFV prodrug or PWH with VS on TFV alafenamide (TAF). We examined TFV-DP in DBS and its association with VS at baseline among…